14/05/2009
The BIG 3-04 MINDACT trial reached its first milestone, the “pilot phase” consisting of the first 800 enrolled patients, in November 2008. The preliminary results of this pilot demonstrate that the trial is feasible from the logistical point of view; that the compliance rate of both physicians and patients is high; and that the overall process is providing good quality data and biological materials. With an average accrual rate of 120 patients per month, the trial is expected to finish recruitment (n = 6000) by the end of 2012.
These results and forecasts are exciting and send a very positive message to the scientific community and to the general public.
An article about MINDACT and the outcomes of the pilot phase was published by the European Journal of Cancer (issue 9).